(Q35621647)

9 August 2017

1 reference

title

Natural history of hepatitis B. (English)

1 reference

9 August 2017

Giovanna Fattovich

1

1 reference

9 August 2017

1 January 2003

1 reference

9 August 2017

Journal of Hepatology

1 reference

9 August 2017

39 Suppl 1

1 reference

9 August 2017

S50-8

1 reference

Hepatitis B: an important public health issue

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

1 reference

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B virus and apparent fulminant non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

High levels of viral replication during acute hepatitis B infection predict progression to chronicity

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural history of hepatitis B virus infection in children.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Genomic heterogeneity of hepatitis B virus (HBV) and outcome of perinatal HBV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Seroconversion from Hepatitis B e Antigen to Antibody in Chronic Type B Hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural history of chronic persistent hepatitis B. Relationship between hepatitis B virus replication and the course of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The development of cirrhosis in patients with chronic type B hepatitis: A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The long-term course of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Factors affecting clearance of hepatitis B e antigen in hepatitis B surface antigen carrier children.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Current therapeutic trends in therapy for chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Response of pre-core mutant chronic hepatitis B infection to lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The natural history of asymptomatic hepatitis B surface antigen carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural history and prognostic factors for chronic hepatitis type B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term follow-up of anti-HBe-positive chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage in HBeAg-negative chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis C Virus Infection in Chronic Hepatitis B Virus Carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Virologic and clinical expressions of reciprocal inhibitory effect of hepatitis B, C, and delta viruses in patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Chronic hepatitis D: a vanishing Disease? An Italian multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Changing pattern of chronic hepatitis D in Southern Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Risk of hepatocellular carcinoma in patients with cirrhosis in Japan. Analysis of infectious hepatitis viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Hepatitis B virus. The major etiology of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

Survival and prognostic indicators in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900139-9

7 January 2021

10.1016/S0168-8278(03)00139-9

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14708678